Suppr超能文献

介绍用于选择在固体口服剂型开发过程中释放测试最适合的体外方法的 OrBiTo 决策树。

Introduction to the OrBiTo decision tree to select the most appropriate in vitro methodology for release testing of solid oral dosage forms during development.

机构信息

Institute of Pharmaceutical Technology, Goethe University Frankfurt, Frankfurt am Main, Germany.

Product Development and Supply, GlaxoSmithKline R&D, Ware, UK.

出版信息

Eur J Pharm Biopharm. 2018 Sep;130:207-213. doi: 10.1016/j.ejpb.2018.07.003. Epub 2018 Jul 3.

Abstract

The EU research initiative OrBiTo (oral biopharmaceutics tools) involving partners from academia, pharmaceutical industry, small medium enterprises and a regulatory agency was launched with the goal of improving tools to predict the absorption of drugs in humans and thereby accelerating the formulation development process. The OrBiTo project was divided into four work packages (WP), with WP2 focusing on characterization of drug formulations. The present work introduces the OrBiTo WP2 Decision Tree, which is designed to assist the investigator in choosing the most appropriate in vitro methods for optimizing the oral formulation design and development process. The WP2 Decision Tree consists of four stages to guide the investigator. At the first stage, the investigator is asked to choose the formulation type of interest. At the second stage, the investigator is asked to identify which type of equipment (compendial/modified/noncompendial) is preferred/available. At the third stage, characteristics of the active pharmaceutical ingredient (API) are evaluated and in the fourth stage of the decision tree, suitable experimental protocols are recommended. A link to the living Decision Tree document is provided, and we now invite the pharmaceutical sciences community to apply it to current research and development projects and offer suggestions for improvement and expansion.

摘要

欧盟研究倡议 OrBiTo(口服生物药剂学工具)涉及学术界、制药行业、中小企业和监管机构的合作伙伴,其目标是改进工具以预测药物在人体中的吸收情况,从而加速制剂开发过程。OrBiTo 项目分为四个工作包(WP),WP2 专注于药物制剂的表征。本工作介绍了 OrBiTo WP2 决策树,旨在帮助研究人员选择最合适的体外方法,以优化口服制剂设计和开发过程。WP2 决策树由四个阶段组成,以指导研究人员。在第一阶段,研究人员被要求选择感兴趣的制剂类型。在第二阶段,研究人员被要求确定首选/可用的设备类型(药典/修改/非药典)。在第三阶段,评估活性药物成分(API)的特性,在决策树的第四阶段,推荐合适的实验方案。提供了一个指向活决策树文档的链接,我们现在邀请药物科学社区将其应用于当前的研究和开发项目,并提出改进和扩展的建议。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验